RESUMEN
PURPOSE: The burden of esophageal cancer continues to rise, and noninvasive screening tools are needed. Methylated DNA markers (MDM) assayed from plasma show promise in detection of other cancers. For esophageal cancer detection, we aimed to discover and validate MDMs in tissue, and determine their feasibility when assayed from plasma. EXPERIMENTAL DESIGN: Whole-methylome sequencing was performed on DNA extracted from 37 tissues (28 EC; 9 normal esophagus) and 8 buffy coat samples. Top MDMs were validated by methylation specific PCR on tissue from 76 EC (41 adeno, 35 squamous cell) and 17 normal esophagus. Quantitative allele-specific real-time target and signal amplification was used to assay MDMs in plasma from 183 patients (85 EC, 98 controls). Recursive partitioning (rPART) identified MDM combinations predictive of esophageal cancer. Validation was performed in silico by bootstrapping. RESULTS: From discovery, 23 candidate MDMs were selected for independent tissue validation; median area under the receiver operating curve (AUC) for individual MDMs was 0.93. Among 12 MDMs advanced to plasma testing, rPART modeling selected a 5 MDM panel (FER1L4, ZNF671, ST8SIA1, TBX15, ARHGEF4) which achieved an AUC of 0.93 (95% CI, 0.89-0.96) on best-fit and 0.81 (95% CI, 0.75-0.88) on cross-validation. At 91% specificity, the panel detected 74% of esophageal cancer overall, and 43%, 64%, 77%, and 92% of stages I, II, III, and IV, respectively. Discrimination was not affected by age, sex, smoking, or body mass index. CONCLUSIONS: Novel MDMs assayed from plasma detect esophageal cancer with moderate accuracy. Further optimization and clinical testing are warranted.
Asunto(s)
Biomarcadores de Tumor/sangre , Metilación de ADN , Detección Precoz del Cáncer/métodos , Epigenoma , Neoplasias Esofágicas/sangre , Neoplasias Esofágicas/diagnóstico , Anciano , Biomarcadores de Tumor/genética , Estudios de Casos y Controles , Neoplasias Esofágicas/genética , Femenino , Humanos , Masculino , Persona de Mediana Edad , Curva ROC , Factores de Intercambio de Guanina Nucleótido Rho/sangre , Factores de Intercambio de Guanina Nucleótido Rho/genética , Sialiltransferasas/sangre , Sialiltransferasas/genética , Proteínas de Dominio T Box/sangre , Proteínas de Dominio T Box/genética , Proteínas Supresoras de Tumor/sangre , Proteínas Supresoras de Tumor/genéticaRESUMEN
BACKGROUND & AIMS: Heme oxygenase-1 (HO-1), an antioxidant defense enzyme, has been shown to protect against oxidant-induced tissue injury. We investigated the role of HO-1 in nutritional steatohepatitis in vitro and in vivo. METHODS: AML-12 hepatocytes were cultured in methionine- and choline-deficient (MCD) medium. Cells were transfected with an adenovirus vector that expressed HO-1 (Ad-HO-1) or incubated with the HO-1 inducer hemin or the HO-1 inhibitor stannic mesoporphyrin for 24 hours. C57BL6 mice and db/db mice were fed MCD or control diets, with or without hemin, for up to 4 weeks. RESULTS: AML-12 cells exposed to MCD medium developed significant steatosis, increased release of alanine aminotransferase, and showed signs of oxidative injury. Incubation with hemin induced HO-1 protein, suppressed steatosis, and reduced levels of alanine aminotransferase and lipid peroxidation. A comparable effect was observed in cells transfected with Ad-HO-1, whereas incubation of these cells with stannic mesoporphyrin completely abolished the Ad-HO-1- or hemin-mediated protection of hepatocytes. Mice injected with hemin significantly attenuated MCD-induced steatohepatitis and increased HO-1 protein and activity. This effect was associated with up-regulation of antioxidant chaperones and enzymes, down-regulation of proinflammatory cytokines, and up-regulation of the anti-inflammatory interleukin-22. Moreover, the reduction in steatosis caused by hemin was affected by up-regulation of peroxisome proliferator-activated receptor-alpha and by down-regulation of sterol regulatory element binding protein-1c. CONCLUSIONS: HO-1 can interrupt progression of nutritional steatohepatitis by inducing an antioxidant pathway, suppressing production of cytokines, and modifying fatty acid turnover. Induction of HO-1 might provide a new approach for treatment of steatohepatitis.
Asunto(s)
Hígado Graso/metabolismo , Hígado Graso/prevención & control , Hemo-Oxigenasa 1/metabolismo , Hepatocitos/metabolismo , Hígado/metabolismo , Animales , Línea Celular , Células Cultivadas , Modelos Animales de Enfermedad , Hemo-Oxigenasa 1/antagonistas & inhibidores , Hemina/farmacología , Hepatocitos/patología , Masculino , Mesoporfirinas/farmacología , Metionina/deficiencia , Ratones , Ratones Endogámicos C57BL , PPAR alfa/metabolismo , Proteína 1 de Unión a los Elementos Reguladores de Esteroles/metabolismoRESUMEN
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily which form heterodimers with retinoid X receptors (RXRs) in nucleus and bind to the PPAR response elements (PPREs) of target genes, leading to a wide spectrum of physiological functions. With an improved understanding of its physiological role, PPARdelta and its agonist have been gaining attention in cancer research in recent years. Despite the paucity of research concerning the direct relationship between PPARdelta and gastric cancer, there is substantial evidence that PPARdelta may play a role in the development of gastric cancer. This review focuses on recent literature describing the role of PPARdelta, especially in its association with nuclear factor-kappaB (NF-kappaB), interleukin-1beta (IL-1beta), cyclooxygenase-2 (COX-2) and Wnt-beta-catenin/TCF-4 pathways on gastric tumorigenesis and highlights critical discrepancies that need to be resolved for a more comprehensive understanding of how this receptor modulates gastric tumorigenesis. The potential role of PPARdelta as a therapeutic target in the treatment of gastric cancer deserves further research focus.
Asunto(s)
PPAR delta/fisiología , Neoplasias Gástricas/etiología , Animales , Factores de Transcripción Básicos con Cremalleras de Leucinas y Motivos Hélice-Asa-Hélice , Ciclooxigenasa 2/fisiología , Proteínas de Unión al ADN/fisiología , Humanos , Interleucina-1beta/fisiología , FN-kappa B/fisiología , Factor de Transcripción 4 , Factores de Transcripción/fisiología , Proteínas Wnt/fisiologíaRESUMEN
BACKGROUND/AIMS: Celecoxib was used in the treatment of inflammation in patients with cirrhosis. However, data on the progression of liver fibrosis after treatment by celecoxib are not available. This study aims to elucidate the effects of celecoxib on cholestatic liver fibrosis in rats. METHODS: Rats underwent bile duct ligation (BDL) for 1 or 2 weeks to induce hepatic fibrosis. Celecoxib was introduced on day 1 after operation. The effects of celecoxib were assessed by comparison of the severity of hepatic fibrosis. RESULTS: Infiltration of inflammatory cells and proliferation of bile ducts was seen after 1 week of BDL and fibrosis was induced after 2 weeks. Reduced alanine aminotransferase (ALT) levels and blunted expression of inflammatory factors [tumour necrosis factor-alpha, interleukin (IL)-1beta and IL-6] were seen in the liver of BDL-treated rats that received celecoxib at week 1. Although celecoxib was sufficient in suppressing the cyclo-oxygenase (COX)-2 expression in the control organ (kidney), it failed to suppress the enhanced hepatic COX-2 expression. At week 2, celecoxib did not alter the ALT level, the severity of fibrosis and hepatic collagen contents. This was associated with unchanged alpha-smooth muscle actin protein expression and tissue inhibitor of metalloproteinase-2 (TIMP-2), matrix metalloproteinase (MMP)-2 and MMP-9 mRNA expressions in the liver. Celecoxib had no effect on the BDL-dependent increase in bilirubin levels at any time point. CONCLUSIONS: The present study provides morphological and molecular biological evidences for the role of celecoxib in cholestatic liver fibrosis. Celecoxib protects against hepatic inflammation in the early stage of BDL rats, but does not have an effect on liver fibrosis.
Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Cirrosis Hepática/prevención & control , Hígado/metabolismo , Pirazoles/farmacología , Sulfonamidas/farmacología , Alanina Transaminasa/metabolismo , Animales , Conductos Biliares/cirugía , Celecoxib , Interleucina-1beta/metabolismo , Interleucina-6/metabolismo , Ligadura , Metaloproteinasa 2 de la Matriz/metabolismo , Metaloproteinasa 9 de la Matriz/metabolismo , Ratas , Inhibidor Tisular de Metaloproteinasa-2/metabolismo , Factor de Necrosis Tumoral alfa/metabolismoRESUMEN
Hepatic COX-2 overexpression is sufficient to induce hepatitis, but its role on liver fibrosis remains unknown. We aim to elucidate possible biological effects of COX-2 in liver fibrosis using both gain-of-function and loss-of-function mouse models. COX-2 transgenic (TG) mice that specifically overexpress the human COX-2 cDNA in the liver, knockout (KO), and wild type (WT) mice were studied in two different murine fibrosis models induced by carbon tetrachloride (CCl(4)) injection or methionine and choline-deficient (MCD) diet. Liver injury was assessed by serum ALT and bilirubin levels and histological examination. Hepatic collagen content was determined by picrosirius red stain morphometry assay and quantitation of hydroxyproline. Hepatic stellate cell (HSC) activation was determined by immunohistochemical analysis of alpha-smooth muscle actin (alpha-SMA). mRNA expression of fibrogenic genes was assayed by real-time quantitative PCR. COX-2 protein was overexpressed in the liver of TG mice compared with WT littermates. CCl(4) or MCD-induced liver fibrotic injury was equally severe in TG and WT mice, as demonstrated by similar elevated levels of hepatic collagen contents. Enhanced COX-2 expression in TG liver did not affect HSC activation and fibrogenic gene expression upon CCl(4) or MCD treatment. Importantly, CCl(4)-treated KO mice did not show significant difference in liver fibrotic damage and fibrogenic gene expression compared with the WT counterparts. This is the first report on the effect of COX-2 in liver fibrosis based on genetic mouse models. The results suggest that COX-2 does not appear to mediate the development of liver fibrosis.